Day One Bio aims to bring new cancer therapies to pediatric patients faster amid evolving financial incentives, such as the ...

Strong private equity investment and strategic M&A in 2024, and a shift toward clinical-stage companies and asset-driven ...

Senti Bio aims to improve cancer therapeutics with customizable gene circuits, or multi-gene constructs capable of ...

Simon-Kucher's industry study reveals barriers and success factors for improving global pricing and marketing access ...

Experts at Crowe Life Sciences offer tips for effectively managing risk associated with third parties such as clinics, retail ...

Evaluate VP of Thought Leadership Daniel Chancellor discusses trends for 2025 as the surge in R&D, coupled with rapidly ...

Inozyme's CEO and chairman Douglas Treco shares his thoughts about the rousing success of the Orphan Drug Act, but cautions rare disease drug developers against sky high and inaccessible drug pricing ...

The pharmaceutical industry sits on a treasure trove of data, brimming with the potential to revolutionize drug development, enhance patient care, and optimize commercial strategies. Yet, this vast ...

The life sciences industry contributed nearly $4 billion to the U.S. economy in 2021 and is expected to continue growing an average 7% to 8% per year over the next five years. With an increasing ...

Materials used in a drug package or device design are fundamental to ensuring a safe and effective drug development program. The recent growth in complex therapeutics has increased demand for ...

A: TODAY, WE ARE USED TO SEEING SHAREHOLDERS use proxy battles to insert their representatives into the board of directors (eg. Medicines Company and Ariad). Further, the makeup of a typical company’s ...